Reply to the letters to the editor 'Differential inﬂuence of vemurafenib and dabrafenib on patients' lymphocytes despite similar clinical efﬁcacy in melanoma' by Schilling et al

Ann Oncol. 2015 Jan;26(1):251-2. doi: 10.1093/annonc/mdu512. Epub 2014 Oct 30.

Authors

D Davar¹, T Choi¹, J M Kirkwood²

Affiliations

¹ Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA.
² Division of Hematology-Oncology, Department of Medicine, University of Pittsburgh Medical Center, Pittsburgh, USA kirkwoodjm@upmc.edu.

PMID: 25361986
DOI: 10.1093/annonc/mdu512

No abstract available